NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis $1.37 +0.03 (+2.16%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$1.34▼$1.3750-Day Range$1.12▼$1.8652-Week Range$0.78▼$12.88Volume14,767 shsAverage Volume2.09 million shsMarket Capitalization$34.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get NKGen Biotech alerts: Email Address Ad Colonial MetalsSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PLUS a little-known loophole that allows investors to move a portion of their savings into silver, tax-free and penalty-free.Just click here now to download our Silver Investing Guide for FREE. About NKGen Biotech Stock (NYSE:NKGN)NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Read More NKGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKGN Stock News HeadlinesJune 12, 2024 | globenewswire.comNKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024June 3, 2024 | globenewswire.comNKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024July 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 23, 2024 | globenewswire.comNKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 20, 2024 | investorplace.comNKGN Stock Alert: The Alzheimer’s News That Has NKGen Biotech Soaring TodayMay 20, 2024 | investorplace.comNKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring TodayMay 20, 2024 | markets.businessinsider.comNKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 20, 2024 | msn.comWhy NKGen Biotech Stock Is Moving Higher MondayJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 20, 2024 | finance.yahoo.comNKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 20, 2024 | globenewswire.comNKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's DiseaseMay 16, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & ExhibitionApril 29, 2024 | marketwatch.comNKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease TherapyApril 29, 2024 | markets.businessinsider.comNKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy - Quick FactsApril 29, 2024 | finance.yahoo.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s DiseaseApril 29, 2024 | globenewswire.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's DiseaseApril 25, 2024 | finance.yahoo.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 25, 2024 | globenewswire.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitSee More Headlines Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/07/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CUSIPN/A CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,940,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-243.41% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.04 Sales & Book Value Annual Sales$80,000.00 Price / Sales416.91 Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.50Miscellaneous Outstanding Shares24,890,000Free Float19,910,000Market Cap$33.35 million OptionableNot Optionable Beta0.60 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Paul Y. Song M.D. (Age 58)CEO & Chairman Comp: $36.58MMr. Sangwoo Park (Age 54)Executive Director Comp: $576kMr. James A. Graf (Age 59)Interim CFO Mr. Pierre Gagnon (Age 52)Chief Operating Officer Ms. Yoonmi KangVice President of Technical OperationsDr. Yong Man Kim Ph.D. (Age 59)Chief Scientific Officer Ms. Denise A. Chua CLSMBA, MT (ASCP), Vice President of Investor Relations & Corporate CommunicationsMs. Irene ChangVice President of Human ResourcesMr. Ryan Park C.F.A.SVP of Financial Planning & Analysis and Corporate StrategyMore ExecutivesKey CompetitorsVaxartNASDAQ:VXRTTevogen BioNASDAQ:TVGNKodiak SciencesNASDAQ:KODOmega TherapeuticsNASDAQ:OMGAOptheaNASDAQ:OPTView All CompetitorsInsiders & InstitutionsSequoia Financial Advisors LLCBought 16,000 shares on 5/1/2024Ownership: 0.070%Paul Y SongBought 75 shares on 12/6/2023Total: $249.00 ($3.32/share)Paul Y SongBought 244 shares on 11/27/2023Total: $702.72 ($2.88/share)Paul Y SongBought 100 shares on 11/21/2023Total: $280.00 ($2.80/share)James A GrafBought 10 shares on 11/20/2023Total: $29.40 ($2.94/share)View All Insider TransactionsView All Institutional Transactions NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed this year? NKGen Biotech's stock was trading at $2.75 at the beginning of 2024. Since then, NKGN shares have decreased by 51.3% and is now trading at $1.34. View the best growth stocks for 2024 here. How were NKGen Biotech's earnings last quarter? NKGen Biotech, Inc. (NYSE:NKGN) posted its quarterly earnings data on Monday, May, 20th. The company reported ($0.25) EPS for the quarter. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NKGN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.